Have you evaluated the performance of IQVIA Holdings' (IQV) international operations during the quarter that concluded in March 2025? Considering the extensive worldwide presence of this clinical testing company, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.

In the modern, closely-knit global economic landscape, the capacity of a business to access foreign markets is often a key determinant of its financial well-being and growth path. Investors now place great importance on grasping the extent of a company's dependence on international markets, as it sheds light on the firm's earnings stability, its skill in leveraging various economic cycles and its broad growth potential.

Being present in international markets serves as a counterbalance to domestic economic challenges while offering chances to engage with more rapidly evolving economies. However, this kind of diversification introduces challenges like currency fluctuations, geopolitical uncertainties and varying market trends.

Our review of IQV's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts.

The company's total revenue for the quarter stood at $3.83 billion, increasing 2.5% year over year. Now, let's delve into IQV's international revenue breakdown to gain insights into the significance of its operations beyond home turf.

Trends in IQV's Revenue from International Markets

Of the total revenue, $1.22 billion came from Europe and Africa during the last fiscal quarter, accounting for 31.97%. This represented a surprise of +1.2% as analysts had expected the region to contribute $1.21 billion to the total revenue. In comparison, the region contributed $1.3 billion, or 32.79%, and $1.16 billion, or 30.96%, to total revenue in the previous and year-ago quarters, respectively.

During the quarter, Asia-Pacific contributed $798 million in revenue, making up 20.84% of the total revenue. When compared to the consensus estimate of $769.83 million, this meant a surprise of +3.66%. Looking back, Asia-Pacific contributed $807 million, or 20.39%, in the previous quarter, and $778 million, or 20.82%, in the same quarter of the previous year.

Prospective Revenues in International Markets

For the current fiscal quarter, it is anticipated by Wall Street analysts that IQVIA will report a total revenue of $3.95 billion, which reflects an increase of 3.5% from the same quarter in the previous year. The revenue contributions are expected to be 31.9% from Europe and Africa ($1.26 billion) and 20% from Asia-Pacific ($789.79 million).

Story Continues

For the full year, the company is expected to generate $16.01 billion in total revenue, up 4% from the previous year. Revenues from Europe and Africa and Asia-Pacific are expected to constitute 31.9% ($5.11 billion) and 20.1% ($3.21 billion) of the total, respectively.

Concluding Remarks

Relying on global markets for revenues presents both prospects and challenges for IQVIA. Therefore, scrutinizing its international revenue trends is key to effectively forecasting the company's future outlook.

With the increasing intricacies of global interdependence and geopolitical strife, Wall Street analysts meticulously observe these patterns, especially for companies with an international footprint, to tweak their forecasts of earnings. Importantly, several additional factors, such as a company's domestic market status, also impact these earnings forecasts.

Emphasizing a company's shifting earnings prospects is a key aspect of our approach at Zacks, especially since research has proven its substantial influence on a stock's price in the short run. This correlation is positively aligned, meaning that improved earnings projections tend to boost the stock's price.

Our proprietary stock rating tool, the Zacks Rank, with its externally validated exceptional track record, harnesses the power of earnings estimate revisions to serve as a dependable measure for anticipating the short-term price trends of stocks.

At present, IQVIA holds a Zacks Rank #4 (Sell). This ranking implies that its near-term performance might underperform the overall market movement. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Assessing IQVIA's Stock Price Movement in Recent Times

Over the past month, the stock has gained 3.5% versus the Zacks S&P 500 composite's 9.1% increase. The Zacks Medical sector, of which IQVIA is a part, has risen 1.4% over the same period. The company's shares have declined 19.3% over the past three months compared to the S&P 500's 3.1% decline. Over the same period, the sector has declined 8.7%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

IQVIA Holdings Inc. (IQV):Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments